Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions
Study Details
Study Description
Brief Summary
To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Test Group Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods. |
Drug: Jaktinib Hydrochloride Tablets
Orally, one tablet at a time
Other Names:
|
| Active Comparator: Reference Group Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods. |
Drug: Jaktinib Hydrochloride Tablets
Orally, one tablet at a time
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Maximum Plasma Concentration (Cmax) Of Jaktinib and its main metabolite ZG0244 [up to 48 hours]
Maximum Plasma Concentration (Cmax)
- Jaktinib and its main metabolite ZG0244 AUC(0-t) [up to 48 hours]
Area under the concentration time curve from time 0 to time of the last quantifiable
- Jaktinib and its main metabolite ZG0244 AUC(0-inf) [up to 48 hours]
Area under the concentration time curve from time 0 to infinity
Secondary Outcome Measures
- Jaktinib and its main metabolite ZG0244 Tmax [up to 48 hours]
Maximum Plasma Concentration (Tmax)
- Jaktinib and its main metabolite ZG0244 t1/2 [up to 48 hours]
Half Life (t1/2)
- Adverse events [Day 1 to Day 12]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18≤ age ≤ 45, male or female;
-
Body weight: ≥50 kg for male, ≥45 kg for female; body mass index (BMI): 19.0-26.0 kg/m^2 (inclusive);
-
Informed consent will be signed before the trial, and the content, process and possible adverse reactions of the trial will be fully understood;
-
The volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study.
Exclusion Criteria:
-
Participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug;
-
Participants with chronic or active gastrointestinal diseases such as esophageal disease, gastritis, gastric ulcer, enteritis, active gastrointestinal bleeding, or gastrointestinal surgery within the past three years and still clinically relevant according to the investigator;
-
Participants with definite diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, metabolic system and other diseases that require medical intervention or are not suitable for clinical trial (such as psychiatric history);
-
With positive alcohol breath test;
-
Volunteers may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Third Hospital of Changsha | Changsha | Hunan | China | 410011 |
Sponsors and Collaborators
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Investigators
- Study Chair: Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZGJAK037